http://www.envita.com/conditions-we-treat/cancer/immunotherapy/ - Immunotherapy for Cancer Treatment is absolutely necessary, and many are lacking it. At Envita, it is not an afterthought but in fact, our focus. The immune system is the first and last defense against cancer, and we believe to be critical for long-term success.

1. Envita's AAIT - a Powerful Immunotherapy
for Cancer
AAIT is an acronym for autologous adoptive immune therapy and defines a therapy
derived from a patient’s own blood, which is re-infused during cancer treatment. There
are abundant strategies for immunotherapy and just as many treatments that can be
referenced as “autologous adoptive immunotherapy.” Clearly, not all options are
deemed comparable.
Envita’s immunotherapy, AAIT, involves 4 major cell types which include:
• Natural killer cells
• Natural killer T cells
• Cytokine-induced killer cells
• Cytotoxic T lymphocytes
The inclusion of Natural killer cells (NKs) and Natural killer T cells (NKTs) are the
predominant focus of Envita’s AAIT immunotherapy serums.
Natural Killer Cells Important in Cancer Prognosis of Cancer
When NK cell numbers and functionality are low, cancer patients are predisposed to
more aggressive tumor growth. And, as disease progresses, such declines are likely to
continue. In both animal and human clinical trials, we have seen that by restoring NK
and NKT function leads to enhanced cellular immune tumor-response and higher
patient survival rates.
Keys to Envita's AAIT Uniqueness

2. 1) Envita's protocol for AAIT is primed to optimize the expansion of natural killer cells –
the single most potent cancer fighting component of the cellular immune system. Most
immune therapies do, in fact, include natural killer cells, yet those that do, simply
expand them in minimal amounts with little activation.
2) Envita's AAIT protocol requires only four to five weeks to grow your cells, so you can,
with a degree of certainty, experience benefits within short duration - while other
immunotherapy approaches call to administer just 100-200 million cells per treatment,
Envita delivers roughly 100 times as many during the sojourn of treatment.
3) Stockpiles of published studies convey the effects of adoptive immune therapy in
cancer patients, wherein Envita has identified and improved upon the very best.
Company protocol demands the highest level of procedure for the expansion and
application of cells for each immunotherapy treatment.
4) Unlike other publications regarding immune therapies, Envita's AAIT immunotherapy
endorses the only one that can be used as a “stand-alone.” Moreover, it may also be
administered in conjunction with other therapies to enhance the cells’ effects in patients
– an enviable benefit. Envita's AAIT immunotherapy is not focused solely on expanding
cells in the laboratory: rather, our aim also includes keeping them active, until which
time, they are reintroduced into the patient’s body.
5) Envita’s AAIT immunotherapy unleashes far greater tumor destruction, or cytotoxicity
than that of other well-regarded cancer cell vaccines / immunotherapy treatments found
randomly throughout the world. In essence, this indicates that Envita’s activated natural
killer cells in AAIT deliver considerably higher tumor obliteration.
6) In summation, the most direct manner with which to contrast Envita’s proprietary
immunotherapy against the others includes its:
a. Quality - based on cytoxicity (how much tumor the immune system can
marginalize). Envita’s AAIT immunotherapy consistently delivers “significantly
greater tumor kill”.
b. Quantity (how many cells you get back) – Envita’s AAIT immunotherapy
battles with 100 times the cell dosage than those others.
c. Sterility (quality control measures) – Envita AAIT immunotherapy is completely
free of contaminants. Any questions concerning Envita's AAIT immunotherapy
may be addressed during consultation with Envita's superb team of physicians
and patient educators. This immunotherapy is offered at Envita’s international
cancer center in Mexico.